Results 231 to 240 of about 86,994 (313)

Targeting the kappa opioid receptor for analgesia and antitumour effects. [PDF]

Br J Anaesth
Lambert DG, Mincer JS.
europepmc   +1 more source

Molecular Regulation of Opioid Receptor Signaling

, 2012
Selena S. Schattauer
openalex   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

The Dynorphin/-Opioid Receptor System at the Interface of Hyperalgesia/Hyperkatifeia and Addiction. [PDF]

Curr Addict Rep
Marchette RCN, Vendruscolo LF, Koob GF.
europepmc   +1 more source

Molecular Mechanisms Regulating Ontogeny of O2- and CO2-Chemosensitivity in Rat Adrenomedullary Chromaffin Cells: Role of Nicotinic ACh and Opioid Receptor Signalling

, 2013
Shaima Salman
openalex   +1 more source

Development of a novel risk score reflecting the relative harm potential of synthetic cannabinoids based on prevalence estimates, well‐documented intoxication cases and basic pharmacological data

Addiction, EarlyView.
Abstract Background and aims While the health hazards of synthetic cannabinoid receptor agonists (SCRAs) are often approximated using in vitro pharmacological parameters as surrogate, this approach fails to consider pharmacokinetic and pharmacodynamic complexity.
Michaela J. Sommer, Katharina Elisabeth Grafinger, Maren Hermanns‐Clausen, Volker Auwärter   +3 more
wiley   +1 more source

Identification of genetic variations in μ opioid receptor in cats. [PDF]

Mol Pain
Sasaki K, Hasegawa J, Ikeda K, Ishikawa T, Kasai S.   +4 more
europepmc   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Exploring Pharmacokinetic interactions between SHR8554, a µ-opioid receptor biased agonist, and Itraconazole in healthy Chinese subjects. [PDF]

Sci Rep
Huang L, Jiang H, Huang Y, Li J.
europepmc   +1 more source

A cost–benefit analysis of the implementation and scale‐up of harm reduction interventions in the Australian Capital Territory

Addiction, EarlyView.
Abstract Background and aims Harm reduction interventions aim to reduce negative consequences of drug use. We aimed to estimate the cost, health impact and economic benefits of current, expanded and new harm reduction interventions for people who use drugs in the Australian Capital Territory.
Anna L. Bowring, Tom Tidhar, Anna Olsen, Christopher Bailie, Kelvin Burke, Rowan Martin‐Hughes, Helen Keane, Paul Dietze, Nick Scott   +8 more
wiley   +1 more source